Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...

Abstract: JavaScript has significantly evolved, broadening its capabilities. However, the uptake of tail call optimization (TCO) remains limited, largely due to concerns about debugging difficulties ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

EPS exceeded forecasts by 15.38%, reflecting effective cost management. Revenue missed expectations by 60.26%, raising concerns about growth prospects. The stock price fell by 5.34% in pre-market ...